TNDM Valuation

Tandem Diabetes Care Inc

Add to Watchlist

Advanced Chart

12.510

+0.72(6.107%)1D

Overview
Forecast
Valuation
Earnings

TNDM Relative Valuation

TNDM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNDM is overvalued; if below, it's undervalued.

Historical Valuation

Tandem Diabetes Care Inc (TNDM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.77 is considered Undervalued compared with the five-year average of -7.34. The fair price of Tandem Diabetes Care Inc (TNDM) is between 29.20 to 124.66 according to relative valuation methord. Compared to the current price of 12.51 USD , Tandem Diabetes Care Inc is Undervalued By 57.16%.

Relative Value

Fair Zone

29.20-124.66

Current Price：12.51

57.16%

Undervalued

-11.51

Trailing

Forward

18.98

EV/EBITDA

Tandem Diabetes Care Inc. (TNDM) has a current EV/EBITDA of 18.98. The 5-year average EV/EBITDA is 173.78. The thresholds are as follows: Strongly Undervalued below -339.85, Undervalued between -339.85 and -83.03, Fairly Valued between 430.59 and -83.03, Overvalued between 430.59 and 687.41, and Strongly Overvalued above 687.41. The current Forward EV/EBITDA of 18.98 falls within the Historic Trend Line -Fairly Valued range.

-13.48

EV/EBIT

Tandem Diabetes Care Inc. (TNDM) has a current EV/EBIT of -13.48. The 5-year average EV/EBIT is 61.23. The thresholds are as follows: Strongly Undervalued below -386.86, Undervalued between -386.86 and -162.82, Fairly Valued between 285.27 and -162.82, Overvalued between 285.27 and 509.32, and Strongly Overvalued above 509.32. The current Forward EV/EBIT of -13.48 falls within the Historic Trend Line -Fairly Valued range.

0.77

Tandem Diabetes Care Inc. (TNDM) has a current PS of 0.77. The 5-year average PS is 5.02. The thresholds are as follows: Strongly Undervalued below -2.32, Undervalued between -2.32 and 1.35, Fairly Valued between 8.69 and 1.35, Overvalued between 8.69 and 12.36, and Strongly Overvalued above 12.36. The current Forward PS of 0.77 falls within the Undervalued range.

5.61

P/OCF

Tandem Diabetes Care Inc. (TNDM) has a current P/OCF of 5.61. The 5-year average P/OCF is 70.74. The thresholds are as follows: Strongly Undervalued below -79.17, Undervalued between -79.17 and -4.21, Fairly Valued between 145.69 and -4.21, Overvalued between 145.69 and 220.65, and Strongly Overvalued above 220.65. The current Forward P/OCF of 5.61 falls within the Historic Trend Line -Fairly Valued range.

6.18

P/FCF

Tandem Diabetes Care Inc. (TNDM) has a current P/FCF of 6.18. The 5-year average P/FCF is -34.03. The thresholds are as follows: Strongly Undervalued below -481.83, Undervalued between -481.83 and -257.93, Fairly Valued between 189.87 and -257.93, Overvalued between 189.87 and 413.77, and Strongly Overvalued above 413.77. The current Forward P/FCF of 6.18 falls within the Historic Trend Line -Fairly Valued range.

Tandem Diabetes Care Inc (TNDM) has a current Price-to-Book (P/B) ratio of 6.34. Compared to its 3-year average P/B ratio of 7.45 , the current P/B ratio is approximately -14.94% higher. Relative to its 5-year average P/B ratio of 11.42, the current P/B ratio is about -44.51% higher. Tandem Diabetes Care Inc (TNDM) has a Forward Free Cash Flow (FCF) yield of approximately -0.97%. Compared to its 3-year average FCF yield of -1.06%, the current FCF yield is approximately -8.02% lower. Relative to its 5-year average FCF yield of -0.28% , the current FCF yield is about 244.98% lower.

6.34

P/B

Median3y

7.45

Median5y

11.42

-0.97

FCF Yield

Median3y

-1.06

Median5y

-0.28

Competitors Valuation Multiple

The average P/S ratio for TNDM's competitors is 3.12, providing a benchmark for relative valuation. Tandem Diabetes Care Inc Corp (TNDM) exhibits a P/S ratio of 0.77, which is -75.32% above the industry average. Given its robust revenue growth of 8.46%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNDM.O

Tandem Diabetes Care Inc

Performance Decomposition

Market capitalization of TNDM decreased by 71.24% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -13.89 to -21.77.

The secondary factor is the Revenue Growth, contributed 8.46%to the performance.

Overall, the performance of TNDM in the past 1 year is driven by Margin Expansion. Which is more sustainable.

8.46%

221.91M → 240.68M

Revenue Growth

56.73%

-13.89 → -21.77

Margin Expansion

-136.43%

11.07 → -4.03

P/E Change

-71.24%